Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Coxsackievirus for treating tumor

A coxsackie virus, tumor technology, applied in the field of virus and tumor treatment

Active Publication Date: 2019-04-05
XIAMEN UNIV +1
View PDF3 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there is no report of Coxsackievirus group B type 3 having oncolytic activity in the field

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Coxsackievirus for treating tumor
  • Coxsackievirus for treating tumor
  • Coxsackievirus for treating tumor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0262] Example 1: Acquisition and preparation of CVB3 and its modified forms

[0263] 1.1 Isolation of enterovirus CVB3 from clinical samples of patients

[0264] (1) The patients' throat swabs and anal swabs are from China, Xiamen Center for Disease Control and Prevention; African green monkey kidney cells (Vero cells; Number: CCL-81 TM ) is preserved by China, Xiamen University, National Engineering Technology Research Center for Diagnostic Reagents and Vaccines of Infectious Diseases, and cultured in MEM medium supplemented with 10% fetal bovine serum, glutamine, penicillin and streptomycin.

[0265] (2) Specimen processing: Fully stir the patient's throat swab and anal swab in the specimen preservation solution to wash off the virus and virus-containing cells attached to the swab, and then store the specimen preservation solution at 4°C 4000rpm high-speed centrifugation for 30min;

[0266] (3) Inoculation and observation:

[0267] A. Spread Vero cells on a 24-well p...

Embodiment 2

[0284] Example 2: In vitro anti-tumor experiments of CVB3 and its modified forms

[0285] 2.1 Viruses and cell lines used

[0286] (1) Viruses: CVB3-WT (SEQ ID NO: 12), CVB3-HRV2 (SEQ ID NO: 13), CVB3-miR133&206T (SEQ ID NO: 14), CVB3- GM-CSF (SEQ ID NO: 15) and CVB3-Anti-PD-1 (SEQ ID NO: 16).

[0287] (2) Cell line: human rhabdomyosarcoma cell RD ( Number: CCL-136 TM ); human colorectal cancer cell line SW1116 ( Number: CCL-233 TM ), SW480 ( Number: CCL-228 TM ) and HT-29 ( Number:HTB-38 TM ); human gastric cancer cell line AGS ( Number: CRL-1739 TM ), SGC7901 (CCTCC deposit number: GDC150), BGC823 (CCTCC deposit number: GDC151) and NCI-N87 ( Number: CRL-5822 TM ); human esophageal carcinoma cell line TE-1 (purchased from the Cell Resource Center, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, number: 3131C0001000700089); human small cell lung cancer cell line DMS114 ( Number: CRL-2066 TM ); human non-small cell lung cancer ce...

Embodiment 3

[0329] Example 3: In vivo anti-tumor experiments of CVB3 and its modified forms

[0330] 3.1 Viruses, cell lines and experimental animals

[0331] (1) Viruses: CVB3-WT (SEQ ID NO: 12), CVB3-HRV2 (SEQ ID NO: 13), CVB3-miR133&206T (SEQ ID NO: 14), CVB3 provided in Example 1 were used in this example - GM-CSF (SEQ ID NO: 15) and CVB3-Anti-PD-1 (SEQ ID NO: 16). Refer to Examples 2.2 and 2.3 for the methods of virus cultivation and virus titer determination, respectively.

[0332] (2) Cell lines: human breast cancer cell line BcaP37 (CCTCC deposit number: GDC206), human non-small cell lung cancer cell line A549 ( Number: CCL-185 TM ), human Burkitt's lymphoma cell line Raji ( Number: CCL-86 TM ), human endometrial cancer cell line Ishikawa (ECACC No.99040201), human cervical cancer cell line Hela ( Number: CCL-2 TM ) and human glioma cell line GBM (primary tumor cell line isolated from patient tumor tissue). The above cells except Raji used RPMI-1640 medium, and other ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of viruses and the field of tumor treatment, in particular to to coxsackievirus B3 (CVB3) and a modification form thereof, a genomic sequence or a cDNA sequence containing the CVB3 or the modification form of the CVB3, or a nucleic acid molecule with a complementary sequence of the genomic sequence or the cDNA sequence, application to treat a tumor of a subject (for example, a human), and application to prepare a pharmaceutical composition for treating the tumor of the subject (such as the human). The invention further relates to a method for treating the tumor, and the method comprises the step that the CVB3 or the modification form of the CVB3, or the genomic sequence or the cDNA sequence containing the CVB3 or the modification form of the CVB3, or thenucleic acid molecular of the complementary sequence of the genomic sequence or the cDNA sequence are applied to the subject needing tumor treating.

Description

technical field [0001] The invention relates to the field of viruses and the field of tumor treatment. Specifically, the present invention relates to coxsackievirus group B type 3 (CVB3) or a modified form thereof, or a nucleic acid molecule comprising the genomic nucleotide sequence of CVB3 or a modified form thereof or a complementary sequence thereof, for use in a subject Use for treating a tumor in a subject (eg, a human), and use in the manufacture of a medicament for treating a tumor in a subject (eg, a human). The present invention also relates to a method for treating tumors, comprising the step of administering CVB3 or its modified form, or a nucleic acid molecule comprising the genomic nucleotide sequence of CVB3 or its modified form or its complementary sequence to a subject in need thereof . Background technique [0002] The current treatment methods for malignant tumors mainly include surgery, chemotherapy and radiotherapy. These traditional therapies are uns...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/768A61K48/00A61P35/00C12N7/00C12N15/41
CPCA61K48/005A61K35/768C12N7/00C07K14/005C12N2770/32621C12N2770/32622Y02A50/30
Inventor 程通王玮夏宁邵叶祥忠侯汪衡付文锟万俊凯
Owner XIAMEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com